Related Experiment Video
Updated: May 27, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Synthesis and Clinical Application of Small-Molecule Drugs Approved by FDA in 2025
Liang Chang1, Min Wang1, Huijie Zhang1
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
None:
In 2025, the U.S. Food and Drug Administration (FDA) continued to advance therapeutic innovation by approving a diverse range of novel drugs. According to the FDA's 2025 Novel Drug Approvals list, 46 new drugs received approval, including both new chemical entities such as Ziftomenib, Sevabertinib, Zoliflodacin, and Gepotidacin, as well as new biologics. These approvals cover a wide range of therapeutic areas, including oncology, rare genetic diseases, infectious diseases, cardiovascular diseases, and immunomodulation. A significant proportion of the approved products navigated accelerated or priority review pathways, reflecting their potential impact on unmet medical needs. This review provides a comprehensive overview of the synthetic routes and clinical applications of FDA-approved small-molecule drugs in 2025, aiming to inspire future development in drug discovery.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Discovery: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Clinical Trials: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Clinically Relevant Drug Product Specifications: Methods of Establishment
